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The emergence of publications on extracellular RNA (exRNA) and extracellular vesicles (EV) has highlighted
the potential of these molecules and vehicles as biomarkers of disease and therapeutic targets. These findings
have created a paradigm shift, most prominently in the field of oncology, prompting expanded interest in the
field and dedication of funds for EV research. At the same time, understanding of EV subtypes, biogenesis,
cargo and mechanisms of shuttling remains incomplete. The techniques that can be harnessed to address the
many gaps in our current knowledge were the subject of a special workshop of the International Society for
Extracellular Vesicles (ISEV) in New York City in October 2012. As part of the ‘‘ISEV Research Seminar:
Analysis and Function of RNA in Extracellular Vesicles (evRNA)’’, 6 round-table discussions were held to
provide an evidence-based framework for isolation and analysis of EV, purification and analysis of associated
RNA molecules, and molecular engineering of EV for therapeutic intervention. This article arises from the
discussion of EV isolation and analysis at that meeting. The conclusions of the round table are supplemented
with a review of published materials and our experience. Controversies and outstanding questions are
identified that may inform future research and funding priorities. While we emphasize the need for
standardization of specimen handling, appropriate normative controls, and isolation and analysis techniques
to facilitate comparison of results, we also recognize that continual development and evaluation of techniques
will be necessary as new knowledge is amassed. On many points, consensus has not yet been achieved and
must be built through the reporting of well-controlled experiments.
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E
xtracellular vesicles (EV) have garnered consider-
able attention because of the specific mechanisms
whereby they are actively released from cells; their
involvement in cell-to-cell signalling; and their utility as
markers of disease (112). Extracellular RNA (exRNA)
is carried and protected within the extracellular milieu by
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and lipoprotein particles (15,16). This RNA includes
microRNA (miRNA), transfer RNA (tRNA), ribosomal
RNA (rRNA), messenger RNA (mRNA), and additional
structural and non-coding RNAs (17,18). Although some
RNAs may be incorporated non-specifically, there is
growing evidence for enrichment of certain RNA species
in specific vesicle types (1,17,18). Along with other EV-
associated molecules, specific EV exRNAs may partici-
pate in signalling processes and serve as molecular
signatures of disease.
Nomenclature
EV are a heterogeneous group, and the nomenclature is
still being defined and refined by the research community
(1921). This process will likely continue for the foresee-
able future because of the many outstanding questions
associated with biogenesis, uptake and other processes
(22). For example, ‘‘exosomes’’ have classically been de-
fined as originating from the endosomal compartment by
fusion of multivesicular bodies (MVB) with the plasma
membrane, whereas ‘‘microvesicles’’, ‘‘ectosomes’’ or
‘‘shed vesicles/particles’’ have been thought to originate
by direct budding from the plasma membrane (16,23). In
the literature, exosomes are often described as smaller
than 100 nm in diameter, while microvesicles are con-
sidered to be larger than 100 nm (7,16,24). However, the
strict separation of these vesicle types by size or biogenesis
has not been established beyond doubt (2527), and there
is currently no consensus on markers that distinguish the
origin of these vesicles once they have left the cell (25). As
numerous participants in the ISEV workshop noted, there
is little evidence that particles less than 100 nm in diameter
cannot bud from the plasma membrane, and EV with
exosome markers may be larger than 100 nm in size.
In terms of biogenesis and markers, retroviral particles are
in reality atype of EV that may be exemplaryof ablurring
of identity of the classic ‘‘exosome’’ and ‘‘microvesicle’’
(25,2730). In using the term EV to describe all classes of
extracellular membrane vesicles, we recognize that the
future will likely bring increased specificity of terms used
in this emerging field and that consensus does not yet
exist.
Biofluids
EV are present in biological fluids (31,32). At least some
EV are associated with exRNA molecules, in which case
the RNA may be referred to as evRNA. EV have been
isolated from biofluids including pleural effusions (33),
plasma (34,35), ocular effluent and aqueous humor (36),
breast milk (35,37), ascites (38,39), amniotic fluid (40,41),
semen (‘‘prostasomes’’ and ‘‘epididymosomes’’) (4250),
saliva (35,41,51,52), nasal secretions (53), cerebrospinal
fluid (CSF) (54), bronchoalveolar lavage (BAL) (5557),
synovial fluid (5865), bile (66) and urine (67,68). EV are
commonly recovered from cell culture-conditioned media
(6971). Vesicles have also been recovered from disso-
ciated tissue [e.g. adipose tissue (72) and thymus (73)];
however, it is difficult to establish the extracellular nature
of these vesicles, as the recovered materials can also
comprise intracellular vesicles released during the tissue
dissociation process.
EV in biological fluids  and the molecules associated
with them, including RNA  may be used diagnostically
for different disease states. Accordingly, they have aroused
considerable interest in the research community and stu-
dies have been initiated for biomarker discoveries in
diseases such as cancers of the urogenital system (bladder,
prostate and ureter), melanoma, and ovarian and primary
brain tumours. These consortia are based on early
explorations of the utility of EV RNA of prostate-specific
antigen (PSA), prostate cancer antigen 3 (PCA3), and the
gene fusion of transmembrane protease, serine 2 and Ets-
related gene (TMPRSS2: ERG) in the urine of prostate
cancer patients (74); the protein claudin-4 in blood EV in
ovarian cancer (75); and the epidermal growth factor
receptor variant EGFRvIII in gliomas (76). Notable is
a multi-institution consortium collaborating to validate
the glioblastoma diagnostic CSF biomarker EGFRvIII
as well as isocitrate dehydrogenase with a codon 132
mutation (IDH1.132) (76). In parallel with these biomar-
ker trials, the utility of EV isolates for vaccination against
cancer includes vaccination trials for melanoma (77) and
non-small-cell lung carcinoma (78) using EV from pa-
tients’ dendritic cells loaded with tumour antigen-derived
peptides,and colorectal cancer withEV from colon cancer
patients’ ascites combined with granulocyte-macrophage
colony-stimulating factor [GM-CSF (38)]. In addition, a
vaccination trial has utilized a group B meningococcal
bacterial outer membrane vesicle with similarities to
mammalian plasma membrane-derived vesicles (79,80).
Need for standardization
In the midst of growing interest in EV, technical standar-
dization is of central importance because many meth-
odologies have been used to isolate and analyze EV.
Following isolation, a variety of techniques have been
employed to purify RNA. The influence of these disparate
techniques on the results of downstream exRNA sequen-
cing and profiling remains unclear, raising the need to
provide a definition of ‘‘best practices’’ and eventual
standardization. As exRNA diagnostic platforms become
available, there will be requirements for clinical certifica-
tion and development of manufacturing standards.
Furthermore, pressurewill emerge todefine andcentralize
biofluids from normative biological controls.
ISEV 2012 workshop on evRNA
To host discussion and foster progress towards resolving
the technical issues of evRNA research, the International
Kenneth W. Witwer et al.
2
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2013, 2: 20360 - http://dx.doi.org/10.3402/jev.v2i0.20360Society for Extracellular Vesicles (ISEV) organized a
meeting in New York City. Under the leadership of
ISEV president Jan Lo ¨tvall and Board Member Marca
Wauben, the ‘‘ISEV Research Seminar: Analysis and
Function of RNA in Extracellular Vesicles (evRNA)’’
was convened on 12 October 2012 (81). Following on
from the Society’s first annual meeting in the spring of
2012 (82), this workshop was attended by an international
and experientially diverse group of participants from
academia and industry. The format included short pre-
sentations as well as 6 round table discussions (Table I).
In this article, we summarize the outcome of the ISEV
workshop discussions and subsequent communications
pertaining to pre-analytical variables in EV research
(chiefly derived from topic 1, Table I). We present study
design considerations, including planning for appropriate
biological normatives, to maximize the utility of EV
research projects. Second, we focus on plasma as an
example through which to review important considera-
tions in sample collection procedures and processing
variables, followed by presentation of challenges specific
to avarietyof additional biological fluids. We evaluate EV
isolation methods and critique quantitative and qualita-
tive methods for EV analysis. Finally, we summarize
several suggestions (see also Table II) to guide progress
in the field.
Study design and normative controls
The goal of EV research projects will influence
isolation procedures
EV research can be broadly divided into 3 categories,
each of which mandates a different level of quality
control and operating procedure. Since many technical
protocols exist, some more closely suited than others to
particular types of research, it is necessary to select
protocols based on the research question.
a. Discovery research characterizes EV quantity, size,
exRNA cargo, proteomics, lipidomics, metabolomics,
glycomics and other characteristics in body fluids. To
discover candidate biomarkers in general EV popula-
tions or those sequestered by size, structure or charge,
attention must be paid to reproducibility of the assay,
minimization of ‘‘non-target’’ EV (e.g. in some but
certainly not all approaches, the broad background of
platelet- and neutrophil-derived vesicles) and optimi-
zation of assay sensitivity. Thus, isolation protocols
are important, but function of isolated EV does not
necessarily need to be preserved.
b. Diagnostic research involves the search for features
that are uniquely or quantitatively associated with
a disease process. In order to validate the clinical
specificity or correlation strength of a marker,
selective EV isolation may be imperative, depending
on the biofluid. A clinically useful test should offer
advantages of increased sensitivity, reduced cost or
lowered morbidity when compared to current diag-
nostic methods when evaluated in a selected patient
population and when compared with appropriate
population controls.
c. Preparative research involves the preparation of
EV to be given to patients (43) or for mechanistic
analyses. This research requires the highest level of
standards aimed both to preserve EV function and to
selectively purify EV.
Normative controls
There is a need to define biofluid-specific normatives for
EV studies as well as standardized methods, research
designs and ‘‘control groups’’ that mirror demographics
of patients except for disease status. For patients, controls
could be relatives accompanying the patient (in particular
if they are sex- and/or age-matched individuals), an
approach common to epidemiologic case-control studies.
Many factors have known or suspected influence on
vesiculation. These include age, gender, body mass index
(BMI) and medication use (e.g. oral contraceptives). As
yet, no systemic studies have investigated the effect of
race- or ethnicity-associated polymorphisms on vesicula-
tion, but, if feasible, it may be advisable to recruit race-
matched controls for the investigations. Among women,
controls should be selected for pregnant, non-pregnant
and multiple pregnancy samples (83). Fasting or post-
prandial status may affect blood plasma lipoprotein and
EV levels (84). Current sickness, including common cold
symptoms, should be assessed since acute infection alters
circulating cells and RNA (85,86). Hospitalization and
Table I. 2012 ISEV Research Seminar discussion topics
Round table Topic Description
1 EV isolation Pelleting, filtration, density gradient, controls
2 RNA isolation Comparison of different isolation protocols
3 evRNA analysis Hybridization, qPCR, RNase treatment
4 evRNA analysis and bioinformatics Deep sequencing, analysis pipelines, recent developments
5 RNA loading and engineered vesicles Electroporation, loading control, cellular production, targeting
6 Analysis of functional evRNA transfer Reporter systems, physiological read-out systems
Standardization in EV research
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sampling) should be matched in test and control groups
(84,8789). Individuals on heparin therapy should be
given special attention because of the interference of
heparin with reverse transcription and PCR (9) and with
EV/recipient cell interaction (90).
Repeated samples from patients may serve as controls
not skewed by individual differences (86). Aliquots can be
used to validate EV isolation, RNA extraction and assay
variability, whereas samples from the same individual
drawn at multiple time points can be used for variability
testing of a particular EV marker. Emphasis should be
placed on matching samples from controls with samples
from patients obtained prior to surgical disease diagnosis
of cancer or cultured proof of infection. Matched intra-
individual pre-disease or pre-infection samples would
provide the ultimate baseline for personalized assays.
Establishment of pre-disease sample banks for indivi-
duals within a healthcare system should be considered
carefully, but widespread implementation is unlikely in
the near future. In the absence of ideal matched controls,
normative samples should be chosen carefully.
Maximizing sample utility in harmony with local and
international ethical and legal standards
The collection and use of samples from human subjects
are governed by complex systems of regulations and
guidelines that often differ by country or other geopoli-
tical entities and even from institution to institution.
For example, the Declaration of Helsinki of the World
Medical Association and the Good Clinical Practice
standard of the International Conference on Harmonisa-
tion aim to protect the rights of individuals in medical
research, while privacy regulations have been enacted in
various locations to control the availability of patient-
specific medical information. To maximize the utility of
each sample, it may be important to draft applications
with the broadest possible language to be compatible
with all conceivable experimental and information re-
quirements. International efforts are also needed to
construct identified and normative donor pools matched
to patient demographics to be studied in harmony with
international standards. For example, in George Church’s
Personal Genome Project (http://www.personalgenomes.
org/), donors volunteer personal genomic materials and
personal information (9193).
Sample size determination
Reliance on sound statistics is needed when estimating
population sizes by which to ‘‘power’’ study design
calculations. That this seemingly obvious consideration
bears emphasis is evident from a recent systematic review
of miRNA microarray publications (not restricted to EV
studies) (94). Almost 40% of reviewed studies drew
conclusions from a sample size of just one in at least
one experimental group, eliminating the possibility of
meaningful statistical analysis (94). Of course, as next-
generation sequencing and other profiling techniques can
Table II. Recommendations: resource development
Resource Rationale Details Resource availability
Centralized normative
control biofluid bank
For rigorous comparison of EV
isolation methods, inter-study
comparisons, and well-controlled
biomarker development
Well-characterized normative
matched biofluid samples (e.g.
blood, CSF, urine, saliva) with ‘‘full
disclosure’’ medical information and
other details
Distribution by NIH or other
repository; researchers would
submit project-specific proposals
for access
Artificial EV spike-in
standards
To standardize recovery of EV and
evRNA from biofluids; to facilitate
independent verification of results
Four or five distinct vesicle sizes,
closely mimicking bioparticles;
loaded or not with markers
(potentially inducible?): fluorescent
protein or specific RNA sequences
Commercial or distributed by a
repository to consortium
members; established
laboratories would be available
for validation studies
Additional funding
mechanisms for
technique and
normative control
development
Disparity of results is dependent in
part on procedural differences that
could be resolved
Examples: head-to-head EV
isolation comparisons;
reproducibility of EV recovery
throughout the day; sample volume
and recovery studies; methods for
determination of cellular/tissue
origin of circulating EV
Standard grant application
procedures
Collaborative sample and
resource sharing
network
Many groups focus on 1 particular
type or size of EVor RNA; studies of
different EV and evRNAs in the
same samples would be useful
Participants could analyze different
aliquots of the same biological fluids
or send EV/fluids for analysis by
laboratories with different focus/
expertise
Website and voluntary
cooperation
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to achieve larger group sizes.
Database submission
Data submission is mandated by most journals (95,96)
and independent studies have found that unavailability of
data is associated with low data or study quality (94,
97,98); however, compliance remains poor (94,99,100).
Investigators should plan to provide to a public database
(101103) complete nucleic acid sequencing and profiling
data, along with detailed technical and analytical meth-
ods. Furthermore, authors are encouraged to submit
EV-related molecular data (RNA, protein and lipid) to
EV-specific databases Vesiclepedia [(104); http://micro
vesicles.org)] and EVpedia [(105); http://evpedia.info/].
Vesiclepedia is a compendium for EV data with contin-
uous community annotation and was created through the
effortsofinvestigatorsassociatedwiththeISEV.Founding
members of the Vesiclepedia have agreed to deposit their
data to make it publically accessible.
Sample collection and processing
We begin our review of sample collection and processing
considerations by examining the major biofluid, blood.
A checklist of information that should be collected is
provided as Box 1. Considerations specific to several
selected additional biological fluids and tissue culture-
conditioned media  each of which has its own composi-
tional complexities  are then provided.
Box 1. A proposed checklist for sample collection and
processing
Background information
Age
Sex
Race/ethnicity
Females: any current pregnancy, gravidity, ovulatory
cycle and menopause state
Hospitalization (recent)
Prior or current anticoagulant treatment or coagulo-
pathy
Heparin therapy
Heparinoids
Aspirin
Known clotting disorder of peripheral veins, lung
(pulmonary embolus)
Current medication list (Including but not limited to
birth control)
Smoker?
Drugs of abuse?
Physical activity-each week
Daily job or home activities
Dedicated physical activity B3 h per week
Physical activity  3 h per week
Sleep pattern (e.g. night shift worker/sleep distur-
bances)
Last food and fluid intake
Additional dietary details if possible
Sample collection and processing (blood)
Time sample obtained
Needle type/other apparatus used
Anticoagulant(s) and tube types
How many millilitres were discarded at initiation of
draw? Was tourniquet removed promptly?
Time interval between draw and centrifugation
Notes on handling (tube kept upright? room tem-
perature?)
Haemolysis and method of assessment
Sample processing details
Rotor type
rcf
k-Factor
time
Sample aliquot details and storage
Were cells obtained? Notes.
Complete blood count?
Flow cytometry panel (specify)?
Other assays performed on blood?
Were additional matched samples collected? (e.g.
plasma and serum, urine, nasal secretions, saliva)
Were samples obtained from an accompanying friend
or family member as a control (for patients)?
Blood
Choice of plasma or serum
For most studies involving isolation of EV RNA, we
encourage biobanking of plasma. Retrieved vesicles are
consistently more abundant in sera than in plasma (106),
and platelet-derived EV released after blood collection
during the process of clot formation (107) may account
for over 50% of EV in serum. Thus, although serum
certainly has appropriate uses (108), plasma is the
physiological medium of EV in the blood. In the majority
of published studies on circulating EV, plasma (and not
serum) sampleswere tested. Some participants in the 2012
ISEV workshop noted that, for some research questions,
the use of serum  and even the presence of platelet-
derived EV released after sample collection  might be
desirable. For example, if plateletswere to contain disease-
specific mutations or nucleic acid profiles, platelet-derived
EV might be diagnostic for some diseases, whereas total
plasma exRNA might not be diagnostic (109). Since most
comparisons of exRNA in plasma and serum have used
whole plasma and serum (109112), not RNA isolated
from purified EV, we recommend that additional studies
be undertaken to increase our understanding of plasma/
serum differences and how they are affected by sample
processing protocols.
Standardization in EV research
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Anticoagulants have one or more modes of action,
including calcium chelation, protease inhibition and
inhibition of platelet activation. With many anticoagu-
lants available, it is perhaps easiest to make a negative
recommendation: use of heparin-based anticoagulants
is discouraged. Whether of exogenous or endogenous
origin (e.g. from mast cells), heparin is associated with
false-negative PCR reads (113115), presumably because
heparin competes with primers and/or enzymes for bind-
ing to nucleic acid (116). In addition to PCR inhibition,
heparin can bind EV, block EV uptake by cells (90), EV
activate platelets (117) or lower the platelet activation
threshold (118). Care should be taken to avoid intravas-
cular ‘‘lines’’ with heparin or heparinoid infusions or
those ‘‘cleared’’ using these materials, and the heparin
treatment status of the patient should be recorded. In the
case of valuable archived samples, it may be necessary to
extract RNA from heparinized blood products. Detection
of nucleic acids has been reported following heparinase
treatment (119121) or through the use of polymerases
that are relatively insensitive to inhibitors (119). If EV-
associated nucleic acids are found exclusively inside
vesicles, extensive washing may also help to remove
heparin prior to RNA isolation, but additional studies
are needed.
The choice of an alternative anticoagulant  for
example EDTA, sodium fluoride/potassium oxalate
(NaF/KOx), or sodium citrate with or without additives
such as dextrose (ACD) or theophylline, adenosine and
dipyridamole (CTAD)  is complicated and might best
be guided by the intended downstream assays. CTAD
blocks activation of platelets and subsequent EV release
(122,123). EDTA may interfere with PCR reactions
(albeit to a lesser extent than heparin), but its presence
may be innocuous or even beneficial for other purposes.
Thus, it may be useful to collect blood in separate tubes
with different anticoagulants. Alternatively, downstream
assay reagents may be chosen with the anticoagulant in
mind. Different polymerases have different sensitivities
to inhibitors (119). Post-collection sample treatment,
for example with NaF/KOx, has been described (119),
but additional work is needed in this area before
firm recommendations can be made. We note that the
Scientific Standardisation Committee of the International
Society on Thrombosis and Haemostasis has recom-
mended the trisodium salt of citrate for EV studies [see,
e.g. (124126)].
The necessity of choosing an anticoagulant to fit the
specific research question is illustrated by a recent report
that the use of calcium chelators promotes rapid associa-
tion of EV with platelets in vitro and thus lowers the
apparent count of EV in blood treated with EDTA, ACD
or citrate alone (127). This effect was not seen with
heparin, prompting the authors of the study to suggest
that heparin should be used when accurate EV counts are
required (127). However, a previous study concluded that
heparin might stimulate the release of EV in vitro (128).
We recommend that additional research be conducted
and published to resolve the important questions of
whether and how specific anticoagulants and combina-
tions thereof (122) affect EV release, function and
downstream assays such as PCR.
Venipuncture and handling
Platelets are susceptible to the activation and release of
platelet-derived EV by physical forces associated with the
blood draw procedure (129), including contact, pressure
and shear forces, so standardization of sampling site,
needle gauge and other variables is recommended (130).
Use of a 21-gauge needle or larger and avoidance of
butterfly systems have been advised for venipuncture to
minimize shear forces (131). However, butterfly cannulae
(132) and smaller needles (133) have been compared with
21-gauge needles with few reported differences (134).
Nevertheless, because different studies have examined
different markers of platelet activation and little has
been published on the effects of draw procedure on
platelet-derived microparticles, standardization is essen-
tial to ensure study-to-study comparability. Following
venipuncture and first accumulation of blood in the
collection tube, the cuff should be removed and the first
several millilitres discarded because of the activating
effects of pressure (133) and contamination by fibroblasts.
Collected blood should be handled gently and pro-
cessed rapidly. Tubes may be inverted 810 times without
shaking for proper mixing with anticoagulant. Tubes
should then be stabilized and vertically positioned prior
to centrifugation with a recording made of bench-top
storage time (135), since the interval between draw and
centrifugation to remove cells and platelets may be
crucial (136). EV may be stable for the first 30 min after
draw (127), but lengthy incubation prior to processing
results in increased EV levels (136). Additional studies of
this parameter would be illuminating.
The circadian system, time of draw and fasting status
Haematologic parameters vary throughout the day (137
139), and slight variations in viscosity have been recog-
nized for several decades (140,141). Recently, circadian
rhythm was found to have a greater effect on platelet
activation than 3 stressors including physical exercise
(142). Leukocyte trafficking and the presence in circula-
tion of pro- and anti-inflammatory cytokines change
throughout the day (143). Large microparticles with
specific surface molecules were found to vary with the
time of day (144). For these reasons, until there are well-
controlled studies designed to explore the effects of
diurnal variation on EV, appropriate comparison of
results is most easily performed for samples that have
been collected at the same time of the circadian day.
Kenneth W. Witwer et al.
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sleepwake cycle should be noted. The effects of food
intake on EVarenot well known, but because lipoproteins
carry RNA and food intake affects circulating lipoprotein
particle type, number and function (145147), it may be
advisable to draw blood at a defined interval after the last
meal. Collection of food intake history could be valuable.
Centrifugation and viscosity measurement/adjustment
Blood should be processed quickly and at room tem-
perature to obtain plasma (or serum, as needed). All
samples to be studied should be spun at the same speed
and with the same rotor type. The viscosity can be
assumed to be roughly the same for most blood samples,
but any suspected disease-related departures from the
norm should be measured (148) and noted since viscosity
has been shown to affect EV pelleting efficiency (149). In
the setting of elevated sedimentation rate, hyperviscosity
IgM syndromes, cryoglobulinaemia and Waldenstro ¨m’s
macroglobulinaemia and monoclonal gammopathy of
undetermined significance (MGUS) (150152) considera-
tion should be given to normalization of viscosity by
dilution prior to centrifugation (149). (Note: In contrast
with whole blood, which is not usually viscosity adjusted
prior to removing cells, it is recommended that at least
some cell-free biofluid products are diluted with buffer
prior to EV isolation; see EV isolation recommendations
below.)
Paired samples and additional data collection
From each sample of blood to be used for EV isolation
and analysis, purification of cells is encouraged to
facilitate comparison of vesicular characteristics such as
lipid, carbohydrate, nucleic acid and/or protein profiles
with those of potential cells of origin. (It should be
recognized that cell purification requirements cannot
be met if gel-barrier Vacutainer tubes are used at the
collection step.) Collection of standard cell and metabolic
panels is also recommended to maximize the utility of
each sample for comparative analyses. For a more exact
quantification, in addition to flow analysis of vesicles,
flow cytometry of cells using antibodies to blood and
other cells should be performed on the cellular fraction
recovered from the body fluid. Since EV in the peripheral
blood may be derived from sources other than blood cells
(153), characterization of endothelial and circulating
tumour cells could also be performed. Obtaining multiple
biofluids from the same patient is also desirable, for
example, matched CSF and plasma samples.
Haemolysis
Haemolysis should be assessed visually and, if necessary,
through spectrophotometric and haemoglobin release
assays (154). When total exRNA is analyzed, haemolyzed
blood products contain higher concentrations of certain
RNAs, including miRs-16 and -451 (155). It remains to
be determined whether RNAs released in this way will
confound the results of evRNA analysis.
Removal of platelets
The extent to which platelets are or should be removed
from plasma confounds the literature (123). There are
protocols for separation of platelet-rich and platelet-poor
plasma [PRP and PPP, respectively, see e.g. (156)], but the
definition of PRP varies, and truly platelet-free plasma is
difficult to obtain. Centrifugation required to remove
all platelets would also eliminate large EV. For filtration,
forces applied to expedite the process may result in
platelet activation or particle fragmentation. Immunose-
lection likely does not remove all platelets. The tolerance
for platelets and platelet-derived EV must be estab-
lished for each research question. For example, disease-
associated mutations (SNPs, indels, rearrangements) may
appear from platelet-derived EV (157). Thus, for certain
exRNA mutations in biofluids, platelet removal may be
preferred, but for others, preference may be given to
inclusion of platelet-derived EV. The same protocol
should be followed to isolate all samples compared in
each study. It may be helpful to determine and report the
initial concentration of platelets in each blood sample,
and to use markers to track platelet contamination in EV
preparations.
Sample collection and processing from
biological fluids other than blood
As noted above, studies of EVin bloodproducts dominate
the literature; however, EV are found in and presumably
serve important functions in many other biofluids. In this
section, we examine several biological fluids and discuss
characteristics of these fluids. This section is not a
comprehensive catalogue of biofluids or a review of EV
research in these fluids, and we do not wish to imply that
the biofluids we discuss here  nasal secretions, saliva,
urine, breast milk, CSF and the ‘‘special case’’ of cell
culture-conditioned medium  are necessarily of greater
interest than the many biofluids that are not reviewed.
Instead, our purpose is to underline the importance of
considering biofluid-specific factors when designing and
executing EV studies, from sample collection to EV
isolation.
Saliva
Saliva is a complex fluid that includes glycoproteins,
antimicrobial compounds and secreted antibodies. It is
produced by 3 major paired glands (the sublingual, sub-
mandibular, and parotid) and additional smaller glands
lining the oral cavity. Relatively few studies have ad-
dressed EVin salivain disease. However, saliva EV may be
markers of oral cancer (158) and the autoimmune disease
Sjo ¨grens syndrome (159). EVin saliva havebeen proposed
to participate in immune signalling (51), and uptake of
these EV by macrophages has been demonstrated (35).
Standardization in EV research
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healing in a novel evolutionary explanation of the ‘‘wound
licking’’ phenomenon (52).
Saliva collection
Factors that should be considered in saliva collection
include sampling location, time, instructions to partici-
pants and collection technique. Since different levels of
salivary analytes may be produced by the different glands
(160), the location of saliva sampling within the oral
cavity may influence results, necessitating standardization
within each study and full disclosure of techniques for
interstudy comparison purposes. So far, most EV have
been analyzed from whole saliva (35,51,161). However,
EV production and composition might differ between
glands, and studies of source-specific saliva, such as the
collection of parotid saliva only (162), might be highly
important.
Salivary analytes vary diurnally (163), so the time
of collection should be standardized. Saliva contents
also change with food and drink intake, smoking (164),
and in response to stressors including physical activity
(165). It has thus been recommended that saliva donors
refrain from smoking; from eating or drinking anything
except water for 1 h before sample collection; and from
strenuous physical exercise prior to collection (166).
Because blood contamination could drastically affect
apparent saliva content (167), samples should be assessed
for the presence of blood. Study participants should not
have brushed their teeth within 1 h of collection and
should not have undergone dental procedures in the
previous days. Any oral disease should be noted. Saliva
collection techniques may be separated broadly into
stimulated and unstimulated (or passive) sampling
(166). For the former, the subject is either given a
chemical stimulus or chews on a substance or device to
stimulate the release of saliva, which may be drooled or
spit into a container or collected with an absorbent
material (a ‘‘salivette’’). Location of collection within the
oral cavity is important since the glands differ in their
relative contribution to stimulated saliva (168). In passive
sampling, the donor empties the mouth of saliva that
collects during a defined period of time in the absence of
stimulation. How stimulation affects EV production and
composition is not currently known, as most studies on
saliva EV have been conducted on unstimulated saliva
(35,51,161). The few studies stimulating saliva production
for the analysis of EV have used 0.42% citric acid
(159,162).
Sample handling and EV isolation
Collected samples should be kept on ice, and considera-
tion should be given to the removal of cells, bacteria and
potential food debris prior to EV isolation. This can be
done by low-speed centrifugation and the utilization of
0.2-mm filters. It is important to remember that the use of
such filters will eliminate many large EV. Vacuum filter
systems may be helpful to use instead of syringe filters,
as clogging of these smaller filters are common when
working with saliva. As for other viscous body fluids,
dilution with PBS is recommended. Isolation of saliva
EV has been performed by differential centrifugation
(35,158,161) and gel filtration (51,169). We recommend
that additional studies be performed, for example, to
determine whether collection of saliva by absorbent
techniques is compatible with EV isolation.
Urine
Urine is increasingly studied as it can be obtained non-
invasively in large volumes and contains EV with
diagnostic potential (170) for renal, bladder, urethral
and prostate diseases including cancers (171,172). RNA
is protected by urinary EV to a greater degree than by
cells in urine (173), and the EV themselves are remark-
ably stable (174).
Collection and study design
If voided urine is collected, attention should be paid to
potential bacterial contaminants. It is advised to consider
characteristics of ‘‘freshly’’ voided urine as distinct from
large residues stored in the bladder. Ease of collection
means that normative controls could be selected from
relatives accompanying the patient (preferably sex- and/
or age-matched individuals). Care must be taken in
situations where the patient but not the control donor
has been advised to fast or follow other dietary changes
due to health procedures.
EV isolation
Several groups have reported that rapid nanomembrane-
based concentration of urinary EV is a reliable alternative
to lengthy ultracentrifugation procedures (170,173,175).
Expedited processing options could speed up the intro-
duction of urine-based diagnostics (173), as could the
utility of frozen urine for EV isolation [as referenced in
(173)].
A characteristic of urine, which may in some cases
complicate EV isolation, is the presence of the Tamm-
Horsfall protein (THP, also referred to as uromodulin), a
major protein component of urine (176). Polymeric THP
may entrap large amounts of EV, which may thus pellet at
low speed (177). Addition of the reducing agent dithio-
threitol (DTT) releases EV from the THP trap. However,
upon addition of DTT to urine samples, monomeric
THP will be still present in EV that are pelleted at high
speed (178). The zwitterionic detergent CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate)
has been proposed recently as an alternative to DTT in
removing THP entanglement, while retaining vesicle
morphology and protein activity (179). Use of sucrose
cushions or gradients with heavy water (but not regular
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from THP complexes (67,177).
Nasal secretions
Pathological changes during airway diseases and inflam-
mation can be monitored by measuring cells and soluble
mediators in nasal secretions and by observing epithelial
remodelling in nasal biopsies (180). EV can be isolated
from nasal secretions (53) and may have altered func-
tion(s) and cargo during respiratory disease. Under-
standing nasal EV is of particular importance since
therapeutic vesicles could be transported to the brain
through the olfactory system (181).
Sample collection
Although the influence of sampling technique on yield,
purity and stability of EV is not currently known, nose
blowing, nasal lavage, suction, swabs and spray and
absorption techniques (182) may result in differences in
cell count, concentrations of soluble proteins and level of
caused irritation to the epithelium (182184). Sampling-
induced epithelial inflammation and damage should be
kepttoaminimum.Since inhaledparticlesvarybyseason,
climate and degree of urbanization (185187), baseline
samples or pools of samples from several collections could
overcome within-subject variations (53). As allergens
induce inflammation in the nasal epithelium, atopic
subjects are likely to be even more sensitive to seasonal
changes (188). Same-season collection and controlling for
atopic status, occupational exposure and degree of
urbanization are recommended. For collection of multiple
samples, protein studies indicate that between-collection
interval should be considered and standardized (182).
Studies are needed to determine if loss of yield through
rapid succession sampling also applies to EV, but the
epithelium and mucus layer may need time to recover
between sampling.
Recovery
After instilling 2.55 ml of saline to each nostril, recovery
rate is approximately 80% but can vary between subjects
(range: 6590%) (180). Loss can be limited by having
the subject close the soft palate and train in the NLF
procedure (182). Keeping the mouth closed during
collection ensures that that fluid collected is from the
nose, and does not include saliva. It is possible that the
yield of nasal luminal vesicles can be improved by
increasing the volume of lavage fluid.
Age and gender
Although knowledge of the production and recovery
of EV in nasal secretions remains limited, it is probably
important to study age- and gender-matched subjects.
Pro-inflammatory molecules and second messenger in
nasal secretions can differ with gender (185,189), and
protein concentration in nasal mucus can decrease with
age (189).
Handling of the collected nasal secretion
Little is known about the best handling of collected
samples for EV studies. However, cells should always be
removed by a gentle centrifugation before the samples are
stored in a freezer. The pelleted cells may be examined for
number of inflammatory cells, as well as contamination
of saliva cells and blood cells to establish the condition of
the collected sample.
Breast milk
Breast milk provides not only the required nutrients
for neonates but is also thought to protect against a
variety of health problems in children including necrotiz-
ing enterocolitis, childhood obesity, severe infections,
as well as reducing the risk of cardiovascular disease
and cancer in later life (190,191). Breast milk is a very
complex fluid consisting of proteins, carbohydrates,
lipids, cells and other biologically important components.
Human breast milk contains non-nutritional bioactive
components, such as maternal cells and antibodies,
chemical mediators, vitamins and enzymes (192). Recent
studies have reported the presence of EV in human breast
milk (35,37,193) and cow’s milk (194196), and several
types of RNA were described to be associated with these
vesicles (35,193,195). Various protocols of differential
(ultra)centrifugation and density gradient ultracentrifu-
gation were used in these studies for isolation of EV. Milk
samples had often been stored at low temperatures before
isolation of EV. This may have affected the milk EV
composition. Although EV in milk were shown to have
immune modulatory effects (37), the role of milk EV in
neonates awaits clarification. Furthermore, EV in milk
are being explored as biomarkers to monitor the devel-
opment of (immune-related) diseases such as allergies.
The selection of patient groups and normative controls
should be carefully considered when studying breast milk
because of the large number of factors that influence
the composition of milk. These factors include the stage
of lactation, parity, volume of milk production, infant
feeding, maternal diet and energy status, maternal health,
illness, and stress (197). For example, the composition of
colostrum (15 days), transitional milk (615 days) and
mature milk differs largely with regard to the concentra-
tion of fat, proteins, vitamins and antibodies (198,199).
Furthermore, it should be considered that, during active
phasing out of breastfeeding, apoptosis events causing
mammary involution (200) may lead to increased num-
bers of EV derived from apoptotic cells in the milk EV
populations.
Isolation of EV from milk is complicated by the high
lipid content of milk. Lipids (mainly triacylglycerols)
are released in milk as fat globules (MFGs) by mammary
epithelial cells. These MFGs are droplets of lipids
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ing proteins and glycoproteins (201), and thus are a type
of EV. MFGs are largely heterogeneous in size, and their
buoyant densities are different from those of other EV
(201). Because of their vesicular nature and high abun-
dance in milk, however, MFGs may be co-isolated with
other EV populations present in milk.
Several lines of evidence indicate that the method of
milk sample collection and storage affects the composi-
tion of milk, and may therefore also influence the EV
content of milk. The method of milk expression (manual
versus electric pump) was shown to influence the fat
content of milk and contaminations derived from the
skin (202). Since the composition of fore and hind milk
has been shown to be largely different (203), milk samples
for research mostly consist of equal volume mixtures
of these two milk types or complete milk of one feed.
Various studies have addressed the influence of low-
temperature storage on breast milk composition [re-
viewed in (202)]. The type of storage container (glass,
polyethylene or polypropylene) has been shown to
influence cell content (202) and could therefore affect
the EV content. Freezing of milk, as is widely performed
for milk banking, reduces cell number (204) and dying
cells lead to contamination of the milk EV population
(E. N. Nolte-‘t Hoen, personal communication). Freezing
milk also leads to loss of bile salt dependency of the bile-
salt-dependant lipases (205), and increased lipase activity
after thawing may affect cell and EV integrity. Addition-
ally, freezing breaks the emulsion between MFG and
the aqueous fraction, which may lead to changes in EV
isolation efficiency and purity. Storage of milk at higher
temperatures can also affect milk composition. Incuba-
tion at 15358C was shown to lead to a decrease in pH
within hours and rapid lipolysis (within 1 h). Importantly,
not only freezing, but also storage at 048C leads to a
reduction in the number of milk cells [(204) and E. N.
Nolte-‘t Hoen, personal communication]. We conclude
that additional EV-specific studies would be helpful to
establish the effects of collection and storage methods on
milk-derived EV and their content.
CSF
CSF bathes the central nervous system and is continually
filtered into the blood. Although CSF typically contains
much lower concentrations of EV than other biofluids
including blood, the presence of EV in CSF has been
reported based on methods including transmission elec-
tron microscopy (TEM) and laser correlation spectro-
scopy (54,206208). Given their potential as reservoirs
for biomarker discovery in neurological disorders, differ-
ent research groups have profiled the EV-associated
proteome and lipidome composition associated with EV
(54,207,208). The identification of protein structure and
modifications within CSF EV may represent a key
component in deciphering RNAprotein interaction
within disease-associated modifications that may be im-
portant elements in induced neurodegeneration. There is
also interest in identifying the key players  proteins and
RNAs  in unconventional EV release mechanisms pro-
minent in neurodegenerative disease pathogenesis (209).
Comprehensive guidelines have been drawn up for
CSF biobanking (210). CSF is collected from lumbar
regions L2/3 or L3/4 according to consent and approved
medical protocol (210). Investigators should be vigilant
for contamination of CSF samples with blood. For EV
concentration, samples are often subjected to differential
centrifugation (54,207,208). As for isolation of EV from
other biofluids, standardization of techniques has not yet
been achieved and will require comparative studies.
For CSF, it may be particularly problematic to obtain
healthy control samples, although such samples appear to
be available commercially (211). Appropriate controls
may be obtained from patients suffering from disorders
other than that investigated in each respective study (e.g.
affective disorders, peripheral neuropathy, persistent
headache, normal pressure hydrocephalus) (212,213) or
those undergoing intra or epidural procedures.
Cultured cell-conditioned medium
EV and evRNAs isolated from biofluids necessarily
have a mixed cellular origin. In some cases, it may be
interesting to analyze specifically vesicles and RNA
recovered from a single cell type. This is easily achieved
by collecting conditioned medium from cultured cells. EV
are generally purified from medium conditioned by cells
for 2448 h, but shorter conditioning times have been
used to analyze specific release of EV-associated markers
after a specific stimulus: for instance, surface receptor-
mediated stimulation (214,215) or fMLP, PMA or
calcium ionophore treatment for 1560 min (1,216,217).
It is important to keep in mind, however, that such acute
stimulations may lead to the release of EV of different
intracellular origin than those secreted spontaneously,
and no extensive side-by-side comparisons of steady-state
and induced EV have been performed to our knowledge
so far. Even in this simplified situation, precautions to
avoid artifactual EV are indicated.
Serum-derived EV
In most cases, cells are cultured in vitro in the presence of
serum. Whether this is human serum or foetal calf serum
(FCS), it contains EVand RNAs. To avoid contamination
of cell-derived vesicles by serum EV, 2 solutions have been
proposed (70). The first is to eliminate serum-derived
vesicles before cell culture by performing an overnight
ultracentrifugation at 100,000g. To allow efficient
elimination of vesicles, and due to the viscosity of serum,
it is mandatory to centrifuge serum diluted to at most 20%
in the culture medium. To make sure that the medium has
been properly depleted from vesicles, quantification by
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classically found in EV, such as transferrin receptor or
flottilin-1, can be performed. The second solution is to
culture cells in serum-free medium. This is possible, for
instance, for the culture of primary neurons, which are
classically cultured in a defined medium with growth
factors. For cells that are normally grown with serum (e.g.
tumour cell lines), but that can survive without serum for
a few days, many laboratories simply change the medium
to serum-free medium for the conditioning time. Such
an abrupt switch to nutrient-poor medium, however, will
unavoidably induce a stress response, most probably
leading to secretion of EV of different composition and/
or intracellular origin. Here again, however, no specific
side-by-side comparisons have been performed yet, and it
would be advisable to perform such comparisons for each
type of cells analyzed. Finally, some commercially avail-
able serum-free media for long-term growth of some cell
lines, such as AIM-V, give rise to a pellet containing
proteins (as quantified by microBCA) and vesicles or
protein aggregates (as quantified by Nanoparticle track-
ing analysis; C. The ´ry, personal observations). Thus, these
media may not entirely circumvent the problem of
contamination by non-cell-derived vesicles.
Cell death
Whatever the culture conditions, it is absolutely necessary
to quantify the percentage of dead cells present in the
culture at the end of the conditioning time. Indeed, dying
cells release vesicles of various sizes, and eventually break
into cell fragments, which can in turn fragment into
smaller vesicles upon ultracentrifugation or filtration.
Presence of abundant dead or dying cells will thus lead
to contamination of live cell-derived EV by dead-cell-
derived vesicles, and current purification protocols will
not separate these different vesicles. Soluble materials
released from dying cells may also adhere non-specifically
to lipid vesicles, and thus change their protein and/or
nucleic acid composition. For these reasons, one might
arbitrarily specify 5% as the maximum acceptable cell
death percentage in culture to provide reasonably pure
EV released by live cells.
Microbial contamination
Finally, microbes may contaminate cell cultures. If con-
ditioned medium is subjected to high-speed pelleting, any
microbial contamination is expected to sit in the pellet.
Authors should be aware of this risk, and first confirm the
Mycoplasma-free status of cells used in their experiments.
Similarly, if cells are productively infected with viruses,
they will co-purify with small EV upon ultracentrifuga-
tion. One could even imagine that endogenous retro-
viruses, normally present in mammalian genomes, may
recombine with genomes of retroviral expression vectors,
and lead to production of new viruses, although this has
never been strictly demonstrated.
EV isolation
Method-independent considerations
Input volumes and dilution
Optimal input volume for EV isolation will likely need
to be determined empirically for each biological fluid
and isolation method. In the case of RNA purification
from EV or fluids, it has been suggested by some (119)
that larger amounts of starting material do not necessa-
rily result in larger amounts of recovered RNA, perhaps
because of clogging or saturation of RNA purification
columns or co-purification of PCR inhibitors. Dilution
of biological fluids with PBS may enhance the recovery
of EV by altering the viscosity of the respective fluid
(149), a principle that was noted as early as 1967 for EV
that was then described as ‘‘platelet dust’’ (218). The ´ry
and colleagues recommended dilution of plasma, ascites,
BAL and other fluids with an equal volume of PBS prior
to centrifugation (70). Others have reported dilution by
factors of 3- to 10-fold (13,108,219). However, the need
for and utility of dilution is viscosity dependent and may
not be necessary for every biofluid.
Storage and handling of collected fluid before EV
isolation
It may be advisable to proceed to vesicle isolation im-
mediately after collecting the biofluid or cell-conditioned
medium that is to be analyzed (136). In some cases,
however, fluid storage before EV purification may be
convenient, for instance to allow simultaneous processing
of samples from different patients or sources. One might
also wish to examine previously biobanked patient
samples. At a minimum, cells and platelets should be
removed from the fluid prior to storage. Beyond this
elementary consideration, little consensus exists, and
reports of well-controlled experiments are needed to
reveal the consequences of fluid storage temperature
(48, 208, 808 or 1608C) and other handling and
storage parameters for the recovery and phenotype of EV.
Storage and handling of isolated EV
Storage vessels, buffer and conditions may each affect
the outcome of EV experiments. Siliconized vessels are
recommended for storage to prevent adherence of EV to
surfaces. At the least, vessels should be tested to ensure
that EV are not partially or completely lost to surfaces.
PBS is the standard choice for resuspension (70), and the
current consensus seems to support storage at 808C.
The effect of additives including dilute, highly purified
protein carriers, awaits detailed investigation. As for any
biological material, it makes sense to minimize freeze/
thaw cycles, although evidence was presented at the
October, 2012 ISEV workshop that small vesicles are
relatively insensitive to freeze/thaw cycles and may even
resist bursting in a hypotonic environment. Resistance
to freeze/thaw has also been reported in the literature
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frozen with frozen and fresh with fresh, and to record
any and all freeze/thaw cycles to which each sample
has been subjected. It should also be clearly indicated
whether vesicles were isolated from fresh or frozen
samples. Finally, samples should be both frozen and
thawed rapidly for maximal preservation of morphology
and function. However, some participants at the ISEV
research workshop reported loss of function following
freezing and advocated use of vesicles stored at tempera-
tures just above freezing. Additional studies are needed to
identify storage and handling methods that allow optimal
retention of function.
Methods
EV isolation may be achieved by a variety of methods,
including ultracentrifugation, filtration, immunoaffinity
isolation and microfluidics techniques. The invention
of the ultracentrifuge by Svedberg around 1920 (221)
led to the extensive development of separation techniques
that were applied to the study of enveloped viruses 
an interesting subset of EV  in the mid-20th century.
Ultrafiltration methods were applied even earlier (222),
while immunoaffinity purification of viruses was per-
formed in the 1970s [see, e.g. (223)]. It is beyond the scope
of this article to present this important historical back-
drop to current EV research. Instead, we will describe the
ground-breaking application and modification of these
methods to investigations of non-viral EV (64,70). These
methods are not necessarily mutually exclusive, and
combinations may be desirable (70,224226). Choice of
method(s) should be guided by the required degree of EV
purity and concentration.
Centrifugation
To date, most published studies of EV from biofluids or
cell culture have employed differential centrifugation with
or without size filtration to concentrate and partially
purify EV (64,70). After depletion of cells, platelets and
large apoptotic bodies by 1 or more low-speed centrifu-
gation steps and/or size exclusion (e.g. 800-nm filter),
larger EV (variously labelled microvesicles/microparti-
cles/ectosomes) are pelleted. Forces commonly reported
for this step are in the 10,00020,000g range. Smaller
EVare then pelleted at high speed (100,000120,000g).
Such stepped ultracentrifugation procedures cannot
achieve absolute separation by size because sedimenta-
tion also depends on the density or ‘‘cargo’’ of a particle
and the distance a particle travels. Some small EV near
the bottom of the tube will pellet in the large vesicle pellet
at low speed (226), while some larger particles near the
top of the tube may pellet only with the high-speed spin.
Aggregation of EV, a common occurrence, also interferes
with separation by individual vesicle size. Similarly, the
pellet from a high-speed spin will contain extravesicular
proteins complexes/aggregates, lipoprotein particles, and
other contaminants. Resuspending and recentrifuging
each pellet in PBS may aid in removing some of these
impurities, albeit at the risk of reducing the yield of EV,
but absolute separation is impossible by this method
alone. For this reason, protein measurements of EV-
containing pellets are inadequate to determine recovery
of EV [we also note that lipids are known to interfere
with detergent-compatible protein assays (227)].
To remove contaminating non-vesicular particles, den-
sity gradients add stringency by separating particles
of different density. By allowing EV to float upward
into an overlaid sucrose gradient, as described in the
original studies of EV (64,70), one can efficiently separate
contaminating protein and/or proteinRNA aggregates,
which will remain at the bottom of the tube, from lipid-
containing vesicles. In addition, this procedure allows
separation ofvesiclesaccording totheirdensity, classically
reported between 1.1 and 1.19 g/ml. Of note, 2 studies
published in 2012 showed that some vesicles take between
62 and 90 h (228,229) to reach equilibrium density, that is
much longer than the traditional 16-h centrifugation time
(70). Thus, performing ‘‘buoyant velocity separation’’ as
proposed by Palma et al.  introducing variable lengths of
centrifugation of the sucrose gradient  may allow more
efficient separation of different vesicles. Finally, another
commonly used approach involves loading the pellet on
top of a sucrose gradient (33,41,42), a sucrose cushion
(171,224) or iodixanol (71) before centrifugation for a few
hours to overnight. If centrifugation is too short and/or
the tube is too long, though, contaminating aggregates
may not reach the bottom of the tube and thus end up in
the same fractions as EV. Since different classes of vesicles
may have overlapping densities, however, even density-
based procedures may achieve enrichment rather than
true isolation. Where reconstitution of biological activity
is required, the effects of ultracentrifugation parameters,
including the influence of sucrose and changing the
osmotic environment, might be carefully assessed.
When reporting results of centrifugation experiments, it
is essential to specify all variables of the centrifugation
procedure (230) to ensure the possibility of reproduction
and study-to-study comparison. Physical separation de-
pends notonlyon theg forceapplied, but also on the rotor
type (fixed angle, swinging bucket), pelleting efficiency
(rotor k-factor), sample viscosity, and gradient character-
istics. Several participants at the ISEV 2012 workshop
encouraged the exclusive use of swinging bucket rotors
during ultracentrifugation. In comparison with a swing-
ing-bucket rotor, a fixed-angle rotor deposits material
against thewallofthe centrifuge tubeand gradually forces
this material down the wall to the bottom of the tube.
There arecompeting viewson whether ultracentrifugation
in general damages EV (220,226). This process is thought
by some to be physically damaging to viruses; effects on
non-viral particles are largely unknown, but aggregation
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compare size, percentage of damaged vesicle, soluble
protein contamination and RNA profiles associated with
different methods.
Size exclusion
Separation of EV based on the size and passage through
physical barriers may be achieved through the use of
filters or chromatography. In the former, particles larger
than the desired size may be excluded, for example by a
filter with a 0.8-mm pore size, or particles smaller than the
desired size range may be removed, while the target
population is retained on the filter. Column chromato-
graphy allows for sequential elution of EV size fractions
from a single column. Filter-based methods will not
enrich EV populations unless low-molecular-weight filters
(e.g. Centricon units) are used for concentration. (How-
ever, little is known about the effects of this concentration
on EVand the extent to which target EV populations may
adhere to the filter and thus be lost to analysis.) For this
and other reasons, size exclusion methods are often
combined with ultracentrifugation or other techniques.
Filers of 0.8 mm are often used to remove large cell
fragments and platelets prior to EV isolation (63), while
0.2 mm filters may be used when smaller EV are desired
(70). Participants at the 2012 ISEV workshop noted that
forcing particles through filter pores may cause deforma-
tion and breakup of large vesicles or platelets, thereby
potentially skewing results. To prevent this, size exclusion
could be performed bygravity (63) or, if this is impractical
because of time considerations, by the smallest possible
applied force. It is also advisable to check that filters do
not release contaminating debris/particles that may inter-
fere with downstream applications.
Immunoaffinity isolation
The presence of characteristic surface proteins on certain
EV classes is the basis for immunoaffinity isolation
(70,231233), in which antibodies to surface proteins
are used to select desired EV populations positively
(immuno-enrichment) or to trap unwanted EV popula-
tions (negative selection or immuno-depletion). Antibo-
dies are associatedwith beads orother matrices (234236)
through covalent or high-affinity interactions, facilitating
physical separation by low-speed centrifugation or mag-
netic techniques. Although commonly used (237), some-
times in combination with other methods (225,238),
immunologic approaches have diverse input requirements,
antibody/antigen combinations and attachment/isolation
systems. As an example of an immunologic approach
to vesicle isolation, HIV-1 virions have been reported to
exclude the cellular membrane tyrosine phosphatase
CD45 (leukocyte common antigen), allowing purification
of virions by negative selection from lymphocyte EV
(239,240). Depending on the approach, this method can
be used to purify and enrich EV.
Immunologic techniques have the potential for high
specificity (241,242), an important consideration in the
characterization of unique EV populations. They may
also be used to select for EV with the correct membrane
orientation, that is vesicles with a cytosolic-outwards
orientation cannot bind antibodies raised to exoplasmic
features. However, selectivity also results in concomi-
tantly lower yields than methods that rely on physical
properties, not least because some markers are possibly
not represented or recognized on all vesicles within a
given class (70). For reporting, it is recommended to
assess not only the presence of selected markers, but also
the absence of contaminants, and to include appropriate
isotype controls.
Polymeric precipitation
With the goal of enriching EV, commercially available
polymeric precipitation mixtures are incubated with
biofluids, typically overnight, and low-speed ultracentri-
fugation is used to collect precipitate that is said to
contain EV or, specifically, ‘‘exosomes’’. These methods,
using reagents such as ExoQuick from System Bios-
ciences, are technically facile and require little hands-on
time (243), but there may be concerns about the purity of
the resulting product. In one study of small EV isolation
from ascites fluid, for example, it was concluded that
polymer-based precipitation was superior than size
exclusion, immunoaffinity separation and ultracentrifu-
gation (244). However, only recovered RNA and protein
purity and quantity were assessed in this study, and the
results would thus be consistent with greater recovery of
RNA or protein through inclusion of impurities. At the
2012 ISEV workshop in New York City, participants
discussed an apparent tendency of polymer-based pre-
cipitation methods to include numerous non-EV con-
taminants such as lipoproteins. In a publication that
assessed exosome morphology following ultracentrifuga-
tion, precipitation and combination methods, it was also
reported that density gradient ultracentrifugation was
preferable even to a precipitation/UC hybrid method for
recovery of high-quality small EV (196). Polymer-based
precipitation may produce highyield of RNA and may be
appropriate in the case of fluids that are thought to have
enriched small EV fractions (245), but rigorous assess-
ment of contaminating particle fractions is recommended
when this method is employed.
Microfluidics
In 2010, Chen, et al. demonstrated rapid recovery of
small EV from both serum and conditioned culture
medium with a microfluidic device containing antibody-
coated surfaces (238). Other micro- and nanofluidics
methods separate nanoparticles based on physical prop-
erties alone (246,247). The application of these methods
to biological fluids has not yet been described extensively.
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Various optical and non-optical methods have been
developed or adapted for the assessment of EV quantity,
size and features such as the presence of specific surface
markers (248). Optimization and standardization of
protocols remain an important task. The following is
an overview of a selection of available techniques, and
some methods that are not covered here may play an
important role in on-going and future EV studies.
Techniques
Electron microscopy
Electron microscopy (EM) techniques are well established
and have provenvery useful in EVresearch (64), providing
direct evidence for the presence of vesicular structures.
The use of heavy metal stains such as osmium tetroxide
and uranyl acetate in TEM enables recognition of
membrane-surrounded vesicles, and contrast is enhanced
by embedding in methylcellulose. In most cases, concen-
trated EV suspensions are applied to grids and fixed, for
example with paraformaldehyde. As an alternative meth-
od, EV pellets at the bottom of a centrifuge tube are fixed,
and ultrathin cross sections are analyzed by TEM (63).
While using suspensions is simpler, sectioning pellets may
be more informative by showing substantially higher
numbers of EV in the EM field and avoiding the
possibility that certain types of suspended EV do not
adhere to the grid. TEM is frequently combined with the
use of immunoglobulins coupled with nanogold particles
that detect specific EV features (immuno-EM). Further
EM tools to investigate EV include scanning EM
(220,249) and cryo-EM. The latter enables the analysis
of EV in frozen samples with the advantage of avoiding
the effects of dehydration and chemical fixatives (250).
For example, cryo-EM results indicate that the cup-
shaped appearance of ‘‘exosomes’’ as reported by TEM
is an artifact of preparation (251). EM is valuable for
assessments of morphology, size and the presence of
markers (by immuno-EM). The technique is of limited use
for concentration measurements.
Atomic force microscopy
In atomic force microscopy (AFM) (252,253), a mechan-
ical cantilever is passed over a surface, with deflections
indicating the presence of surface structures. With the
possibility of sub-nanometre resolution, AFM is parti-
cularly suited to assessments of EV morphology. AFM
has been applied to the study of EV in numerous
publications [e.g. (63,254,255)].
Optical single particle tracking
Nanoparticle tracking analysis (NTA) is the commercial
name of an optical particle tracking method for obtaining
concentration and size distribution of EV populations
(256258). A laser beam is scattered by particles in the
sample,andthemeanvelocityofeachparticleiscalculated
by the StokesEinstein equation on the basis of Brownian
motion recorded by a CCD camera. For accurate quanti-
fication of number and size of heterogeneous populations
of vesicles, the procedure requires accurate optimization
of camera and analysis settings, and separate measure-
ments with different settings may be needed to obtain
accurate readings for EV subsets in heterogeneous mix-
tures. A technical article published recently in Journal of
Extracellular Vesicles should help with standardization of
these procedures (259). Although standard light scatter
NTA does not detect biochemical composition or cellular
origin of vesicles, analysis of fluorescently labelled vesicles
is also feasible (256,260). This, too, requires optimization,
and as yet is not used routinely. Of note, prior to NTA
analysis of biofluid EV, for example from blood, isolation
of vesicles by centrifugation orother means is necessary in
order to remove lipoprotein particles, protein complexes
and other particles that may have similar size and out-
number EVin the blood. Indeed, whenusing NTA in light
scatter mode, one might keep in mind that large protein
aggregates will not be distinguished from vesicles with
similar Brownian motion, and thus even after partial
purification, the particle concentrations calculated by this
technique include a mixture of EV and non-vesicular
structures. As for flow cytometry, it could be useful to
compare samples treated or not with detergents to
eliminate vesicles (see ‘‘Flow cytometry’’ section), but the
influence of detergent on NTA-based analysis requires
further investigation.
Resistive pulse sensing
Resistive pulse sensing, commercialized as the IZON
qNano technique, is a novel alternative to NTA for
concentration and size distribution measurements. This
technique detects individual EV by transient decrease
of an ionic current caused by the transport of a vesicle
through a nanopore in a membrane (261263). Polydis-
perse systems, such as heterogeneous vesicle populations,
often require the combination of results obtained using
more than 1 nanopore membrane (each of which is used
for detecting a limited size range of particles).
Dynamic light scattering
Dynamic light scattering (DLS) calculates the average size
of relatively monodisperse populations of isolated parti-
cles (220,257,258). DLS has also been used for analysis of
EV (226,264). However, for the analysis of heterogeneous
EV populations, this technique is less suited, and results
may vary depending on analysis software.
Flow cytometry
Flow cytometry is a powerful method for both the
qualitative and quantitative characterization of cells
and smaller particles, including EV. For single vesicle-
based flow cytometry, conventional flow cytometers have
a lower detection threshold around 500 nm and are suited
Kenneth W. Witwer et al.
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Megamix bead gating strategy was an important step
towards standardization of flow cytometric assessment of
larger EV (265,266). Newer instruments such as Gallios
(Beckman Coulter), BD-Influx (Becton Dickinson) and
Apogee (Apogee Flow Systems) enable discrimination of
particles as small as 200 nm (268) or even 100 nm in
diameter (266,268,269). The issue of appropriate size
standards, that is polystyrene beads with high refractive
index, silica particles with slightly lower refractive index,
or other materials, has been the subject of some discus-
sion (270). Light scatter-based flow cytometry detection
of EV may be confounded by protein aggregates, includ-
ing clumps of fluorescently labelled detection antibodies
(271). To circumvent this problem, differential detergent
lysis has been suggested to distinguish EV from protein
aggregates during flow cytometry (272). Investigators
who use this approach may wish to demonstrate carefully
that EV are appropriately eliminated, since some lipid
domains of EV are relatively insensitive to weaker
detergents (233,273). Calcium-phosphate microprecipi-
tates were also shown to result in EV-mimicking signals
by flow cytometry (274).
Recently, a protocol was published for high-resolution
flow cytometry detection of fluorescent EV subjected to
flotation on sucrose, and using custom-made settings
of the BD-Influx (Becton Dickinson) (269). This method
overcomes the interference by protein aggregates or
calcium-phosphate microprecipitates. However, analysis
of small vesicles by flow cytometry requires very careful
controls performed using identical settings, including
display of the plots and quantifications collected and
calculated from the diluent alone, and from standard
beads of a similar size and preferably with a comparable
refractive index to that of the analyzed vesicles. Further-
more, serial sample dilutions should be analyzed to define
the proper dilutions at which ‘‘swarm’’ signals generated
by multiple vesicles and detected as a single event are
minimized or excluded [(275) and M.H. Wauben, perso-
nal communication].
To allow easy analysis of EV by flow cytometry, it is
possible to couple EV to micrometre-sized latex beads
(70). In this way, the relative presence of various surface
proteins can be determined, but this method will neither
allow EV quantification nor discriminate between differ-
ent vesicle subsets.
Western blot
Conventional Western blotting may be used to demon-
strate the presence of proteins reportedly associated with
EVor EV subgroups in preparations that include EV, but
is not suitable for determining EV quantity. Markers
might include tetraspanins (CD9, CD63, CD81, CD82),
MHC molecules, or milk-fat globule-EGF-Factor VIII
(MFGE8, or lactadherin), and cytosolic proteins such
as certain stress proteins, Tsg101, Alix, or cytoskeletal
proteins (e.g. actin, tubulin). Purified vesicle preparations
or pellets of fractions of sucrose density gradient ultra-
centrifugation may be treated with buffered solutions
containing lysis reagents, denaturants and protease
inhibitors or directly mixed with loading buffer. Proteins
may then be separated by SDS-PAGE. It is important to
emphasize that this technique on its own cannot identify
whether detected proteins are from EV, and, as discussed
below, that the presence or enrichment of an EV marker
does not mean that contaminants are absent. Never-
theless, the Western blot is a useful tool for detecting
proteins present in purified EV preparations.
Contaminants of vesicle preparations
In addition to EV contaminants (that is, EV other than
those of the desired class), lipoproteins, microbes, micro-
somes, chromatin and protein aggregates may co-purify
in vesicle preparations and confound analysis. Therefore,
caution is warranted when describing a given vesicle
preparation.
Diverse populations of vesicles in preparations
Biological systems contain diverse populations of EV.
Of note, current evidence suggests that the repertoire
of vesicles secreted by cells is dynamic and varies from
cell to cell. In spite of recent efforts to purify a single type
of vesicles (such as exosomes as defined by different
research groups), preparations usually contain more than
1 population. Even preparations isolated by sucrose
gradient ultracentrifugation have been shown to contain
diverse types of vesicles (276278). Evaluation and re-
evaluation of putative markers of specific vesicle types is
in progress, and additional efforts are needed. Even in the
case of markers with strong evidence for EV subtype-
specificity, the presence of such markers does not rule out
that other types of vesicles are present in a preparation
simultaneously. Not only must the desired population be
confirmed as present; contaminants must be demon-
strated to be absent.
Lipoprotein particles
When vesicles are isolated by high-speed ultracentrifuga-
tion, most large lipoproteins will be excluded from the
pellet by their buoyancy. However, some particles  in
particular,high-densitylipoprotein,HDL  mayco-purify
with EV. Although HDL particles are approximately
10 nm in diameter, and thus are substantially smaller
than EV, their density overlaps that of EV (15). Direct
interactions are also a possibility. Even EV preparations
isolated by sucrose gradient ultracentrifugation (1.13
1.19 g/ml) may contain contamination by HDL. How 
andif  toseparateHDLandothercontaminantsfromthe
target vesicle population(s) depends on the goals of each
project. Given that HDL has been shown recently to
transport RNAs (15,16), attempts should be made to
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associated RNA in blood plasma samples. Direct pelleting
of small EV and HDL at 100,000 and 300,000g,
respectively may discriminate between the 2 types of
particles (15).
Microbes
The size ranges of EV overlap those of viruses and
bacteria (125), and any EV preparation is potentially
subject to microbial contamination. EV preparations may
contain virions or virus-like particles, including those of
endogenous retroviral origin. Use of Optiprep (iodixanol)
gradients has been shown to separate virions from small
EV (71). Most bacteria, in contrast, are usually pelleted at
low speed during differential centrifugation (see the ‘‘Cell
culture-conditioned media’’).
Microsomes
Disrupted membrane fragments released by eukaryotic
cells undergoing necrosis may re-form vesicular artifacts
referred to as microsomes. Contributing membranes
include but are not limited to endoplasmic reticulum.
Microsomes may be smooth or rough (the latter carry
numerous membrane-bound ribosomes). Microsomes
pelleted at high speed (100,000g) are potential sources
of ribosomal RNA in EV preparations. The presence of
endoplasmic reticulum proteins (such as calnexin) may be
an indicator of microsomal contamination. As mentioned
above, immuno-isolation techniques may aid in selecting
non-microsomal vesicles.
DNA and other products of necrosis
Organelles and macromolecules including DNA may
be released by necrotic cells. DNA/chromatin networks
known as ‘‘neutrophil extracellular traps’’ (NETS) are
also released as an antimicrobial defence mechanism
(279,280). DNA, on its own or associated with chromatin
proteins, may bind to EV, creating aggregates with greatly
altered buoyant density. Because these aggregates would
pellet at low speed, DNA contamination may result
in reduced yields of vesicles purified with differential
centrifugation and ultracentrifugation. DNase diges-
tion or gDNA eliminator columns may be necessary to
remove DNA contamination of EV samples.
Protein aggregates
Protein aggregates may share biophysical parameters
(including sedimentation properties) with EV (63,281).
Protein aggregates (such as immune complexes) may
pellet along with larger EVat low speed, and are possible
contaminants of extracellular preparations isolated from
biological fluids. As stated before, segregation of EV from
protein aggregates can be achieved by gradient density
ultracentrifugation.
Expectations and proposals
In this position paper, we have summarized discussions
that took place at and following the ISEV research
workshop in New York City in October, 2012. There
exists surprisingly little consensus within the research
community on a variety of technical and biological
questions. As a result, scientific controversies may simply
reflect competitive isolation or analysis strategies. In
addition to reviewing issues of sample design, collection,
processing; EV isolation; and EV analysis; we also issue
several recommendations (Table II). An immediate need is
for normative samples from the general healthy popula-
tion. To ensure adequate supply, multiple pools of
individual samples could be produced. These sample
pools would be held by one or more central repositories
and distributed to researchers on request. In future, it may
be desirable to expand the types of stored sample to
include those from groups with sedentary versus active
lifestyle, high- or low-calorie diet, young and old, male
and female, among other characteristics, to provide better
matches for disease studies. Similarly crucial is the
development of marker-containing and differently sized
artificial biomimicks of EV. These vesicles are needed as
standards and would be spiked into biological samples to
assess isolation efficiency and thus furnish technical
normalization. An artificial standard, for example, loaded
with a specific RNA sequence, would also allow indepen-
dent validation of results. Reliable standards could
demonstrate that a particular isolation method retains
function  RNA transfer capacity  of isolated EV. These
standards, perhaps along with calibration standards for
the various EV quantitation and sizing technologies,
could be made available commercially or distributed
through a repository to consortium members.
Of course, strides forward in this field will be possible
only with the support of funding agencies such as the
European Community and the National Institutes of
Health (NIH) of the United States. We applaud the
European Metrology Research Program (EMRP) project
MetVes (EMRP-MetVes, http://www.metves.eu), de-
signed for metrological characterization of EV from
body fluids and the European Cooperation in Science
and Technology (COST) program ‘‘Microvesicles and
Exosomes in Health and Disease (ME-HAD)’’ (http://
www.cost.eu/domains_actions/bmbs/Actions/BM1202).
We are also pleased by the NIH Common Fund initia-
tive for exRNA (http://commonfund.nih.gov/exrna/), in
which funds have been dedicated to projects involving
discovery and validation of exRNA biomarkers of disease
diagnosis, prognosis and response to therapy; develop-
ment of novel exRNA-based therapeutics; and examina-
tion of the normal distribution and function of exRNA in
various body fluids. We encourage further development
of funding opportunities to resolve the many outstanding
technical and biological questions of EV and evRNA
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